Resultados
Labiana, the pharmaceutical group specialized in animal and human health and listed on BME Growth, has been nominated in the “Best Sustainable Growth on BME Growth” category at the second edition of the Estrategias de Inversión Listed Companies and Investment Funds Awards.
Labiana, returns once again to the Medcap Forum, the leading event for small- and mid-cap listed companies and institutional investors. Organized by BME, the forum will take place from May 26 to 28 at the Madrid Stock Exchange.
Labiana multiplied its profit by twelve in 2025 and reached €75.2 million in revenue, up 13.5%, with balanced growth, margin stability and lower net leverage.
Labiana participará en el Congreso Internacional ANEMBE 2026 en Valladolid, donde presentará sus últimas novedades en salud bovina y reafirmará su compromiso con la innovación, la calidad farmacéutica y el uso responsable de medicamentos veterinarios.
Labiana is publishing an informative guide to help its shareholders understand how subscription rights work and the different alternatives available during the capital increase.
Labiana Health has been recognized as a success story on BME Growth by Bolsas y Mercados Españoles (BME), which highlights the company’s evolution since its IPO and its growth as a pharmaceutical group specializing in human and animal health, being the first veterinary pharmaceutical laboratory to be listed on the stock exchange in Spain.
Labiana Health has secured €37 million in syndicated financing and will execute a pre-emptive capital increase. The transaction enhances its credit profile and supports organic and inorganic growth.
Labiana has completed the validation of the analytical methods for cannabis flowers intended for therapeutic use according to the European Pharmacopoeia. This allows the company to certify producers or distributors worldwide that their batches comply with the specifications required by current regulations.
In recent years, medicinal cannabis has attracted significant interest within the medical and scientific communities. The most studied and recognized compounds of this plant are tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which possess important therapeutic properties. However, terpenes—also present in cannabis—have begun to gain relevance in research due to their potential effects on the modulation and synergy with cannabinoids. This article explores the role of terpenes within the context of medicinal cannabis, highlighting their importance in the development of new treatments.
Labiana Health, the Spanish pharmaceutical group specializing in human and animal health, has published a communication through BME Growth, the Spanish alternative stock market where it is listed, disclosing an unaudited preliminary report on its consolidated financial results for the first half of the fiscal year in 2025.